Aqua-Med Consulting S.R.L.
- Address
- lock Available on a paid plan
Immune System Diseases
The research team at Aqua-Med Consulting S.R.L. is investigating innovative treatments for autoimmune conditions, aiming to lessen systemic inflammation and improve quality of life.
- Primary Sjögren’s disease
- Systemic sclerosis
Current studies assess the benefit of efgartigimod in reducing disease activity for Sjögren’s syndrome and explore BI 685509 as a strategy to preserve lung function and address multi‑organ involvement in systemic sclerosis.
Musculoskeletal Diseases
In the musculoskeletal arena, the site focuses on chronic inflammatory joint disorders, seeking therapies that can halt disease progression and relieve pain.
- Axial spondyloarthritis
One trial evaluates the effectiveness of filgotinib in managing spinal inflammation and improving functional outcomes for patients with active axial spondyloarthritis.
Skin and Connective Tissue Diseases
Research efforts are directed toward disorders affecting the skin, vessels, and connective tissues, with the goal of discovering agents that modify disease pathways.
- Systemic sclerosis
- Primary Sjögren’s disease
Studies aim to evaluate how novel compounds can improve skin elasticity, reduce fibrosis, and mitigate systemic symptoms, thereby enhancing overall patient health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Boehringer Ingelheim Espana S.A.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Boehringer Ingelheim Espana S.A.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Aqua-Med Consulting S.R.L.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 randomized, placebo-controlled, double-blind, parallel-group program to evaluate efficacy and safety of filgotinib in adult subjects with active axial spondyloarthritis | Alfasigma S.p.A. | Phase III | Not Recruiting | Jun 2023 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol | 1 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.